MeiraGTx Holdings (MGTX) reported a Q2 net loss Thursday of $0.76 per diluted share, wider than its loss of $0.46 a year earlier. Four analysts polled by...
MeiraGTx Holdings (MGTX) said Wednesday it has obtained a term loan from Perceptive Advisors for up to $100 million, including $75 million upon closing....
MeiraGTx Holdings (MGTX) said Tuesday it has seen encouraging data from a phase 1/2 clinical study of botaretigene sparoparvovec to treat patients with...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%,...
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%,...
| Address | 430 East 29th Street New York, New York 10016 |
| Phone | +1.646.860.7985 |
| Number of Employees | 68 |
| Recent SEC Filing | 08/11/2022 10-Q |
| President, Chief Executive Officer & Director | Alexandria Forbes |
| Chief Operating & Financial Officer | Richard Giroux |
| Chief Medical Officer | Robert K. Zeldin |
| Chief Development Officer | Stuart Naylor |
| Price Open | $10.13 |
| Previous Close | $9.83 |
| 52 Week Range | $6.59 - 24.89 |
| Market Capitalization | $469.0 M |
| Shares Outstanding | 44.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/10/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.96 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -224.55% |
| Return on Equity | -47.00% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
